Protara Therapeutics, Inc. (TARA) DCF Valuation

Valoración de DCF de Profara Therapeutics, Inc. (Tara)

US | Healthcare | Biotechnology | NASDAQ
Protara Therapeutics, Inc. (TARA) DCF Valuation
  • ✓ Completamente Editable: Adáptelo A Sus Necesidades En Excel O Sheets
  • ✓ Diseño Profesional: Plantillas Confiables Y Estándares De La Industria
  • ✓ Predeterminadas Para Un Uso Rápido Y Eficiente
  • ✓ No Se Necesita Experiencia; Fáciles De Seguir

Protara Therapeutics, Inc. (TARA) Bundle

Get Full Bundle:
$25 $15
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7
$12 $7

TOTAL:

¡Simplifique la valoración de Profara Therapeutics, Inc. (TARA) con esta calculadora DCF personalizable! Con Real Protera Therapeutics, Inc. (TARA) Financials y aportes de pronóstico ajustables, puede probar escenarios y descubrir el valor razonable de Profara Therapeutics, Inc. (TARA) en minutos.


Discounted Cash Flow (DCF) - (USD MM)

Year AY1
2019		 AY2
2020		 AY3
2021		 AY4
2022		 AY5
2023		 FY1
2024		 FY2
2025		 FY3
2026		 FY4
2027		 FY5
2028
Revenue .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Revenue Growth, % 0 0 0 0 0 0 0 0 0 0
EBITDA -7.8 -33.8 -46.1 -64.6 -43.3 .0 .0 .0 .0 .0
EBITDA, % 100 100 100 100 100 100 100 100 100 100
Depreciation .0 .2 1.2 .2 .3 .0 .0 .0 .0 .0
Depreciation, % 100 100 100 100 100 100 100 100 100 100
EBIT -7.8 -34.0 -47.3 -64.8 -43.6 .0 .0 .0 .0 .0
EBIT, % 100 100 100 100 100 100 100 100 100 100
Total Cash 6.2 168.6 91.2 84.4 65.6 .0 .0 .0 .0 .0
Total Cash, percent .0 .0 .0 .0 .0 .0 .0 .0 .0 .0
Account Receivables .0 .0 .0 .5 .2
Account Receivables, % 100 100 100 100 100
Inventories .0 .0 1.2 1.2 .0 .0 .0 .0 .0 .0
Inventories, % 100 100 100 100 100 100 100 100 100 100
Accounts Payable .7 .9 1.0 1.6 2.4 .0 .0 .0 .0 .0
Accounts Payable, % 100 100 100 100 100 100 100 100 100 100
Capital Expenditure .0 -.9 -.6 -.1 .0 .0 .0 .0 .0 .0
Capital Expenditure, % 100 100 100 100 100 0 0 0 0 0
Tax Rate, % 0 0 0 0 0 0 0 0 0 0
EBITAT -7.7 -33.5 -47.1 -63.7 -43.6 .0 .0 .0 .0 .0
Depreciation
Changes in Account Receivables
Changes in Inventories
Changes in Accounts Payable
Capital Expenditure
UFCF -7.0 -34.0 -47.7 -63.4 -41.1 -2.2 .0 .0 .0 .0
WACC, % 12.19 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2 12.2
PV UFCF
SUM PV UFCF -2.0
Long Term Growth Rate, % 2.00
Free cash flow (T + 1) 0
Terminal Value 0
Present Terminal Value 0
Enterprise Value -2
Net Debt -34
Equity Value 32
Diluted Shares Outstanding, MM 11
Equity Value Per Share 2.84

What You Will Get

  • Editable Forecast Inputs: Easily modify key assumptions (growth %, margins, WACC) to explore various scenarios.
  • Real-World Data: Protara Therapeutics, Inc. (TARA) financial data pre-loaded to facilitate your analysis.
  • Automatic DCF Outputs: The template automatically computes Net Present Value (NPV) and intrinsic value for your convenience.
  • Customizable and Professional: A refined Excel model that adjusts to meet your valuation requirements.
  • Built for Analysts and Investors: Perfect for evaluating projections, validating strategies, and enhancing efficiency.

Key Features

  • 🔍 Real-Life TARA Financials: Pre-filled historical and projected data for Protara Therapeutics, Inc. (TARA).
  • ✏️ Fully Customizable Inputs: Adjust all critical parameters (yellow cells) like WACC, growth %, and tax rates.
  • 📊 Professional DCF Valuation: Built-in formulas calculate Protara’s intrinsic value using the Discounted Cash Flow method.
  • ⚡ Instant Results: Visualize Protara’s valuation instantly after making changes.
  • Scenario Analysis: Test and compare outcomes for various financial assumptions side-by-side.

How It Works

  • 1. Access the Model: Download and open the Excel file featuring Protara Therapeutics, Inc. (TARA) preloaded data.
  • 2. Adjust Key Inputs: Modify essential parameters such as growth projections, WACC, and capital investments.
  • 3. Analyze Results Immediately: The DCF model automatically computes intrinsic value and NPV in real-time.
  • 4. Explore Different Scenarios: Evaluate various forecasts to assess diverse valuation possibilities.
  • 5. Make Informed Decisions: Deliver expert valuation insights to enhance your strategic choices.

Why Choose This Calculator?

  • User-Friendly Interface: Perfect for both novices and seasoned professionals.
  • Customizable Inputs: Adjust parameters to suit your financial analysis needs.
  • Real-Time Valuation: Monitor immediate changes to Protara Therapeutics' valuation as you tweak inputs.
  • Preloaded Data: Comes with Protara Therapeutics' actual financial information for swift evaluations.
  • Relied Upon by Experts: Favored by investors and analysts for making well-informed choices.

Who Should Use This Product?

  • Pharmaceutical Students: Understand drug development processes and analyze real-world case studies.
  • Researchers: Utilize advanced models in your studies on biotechnology and therapeutics.
  • Healthcare Investors: Evaluate your investment strategies and assess valuation metrics for Protara Therapeutics, Inc. (TARA).
  • Market Analysts: Enhance your analysis with a customizable financial model tailored for biotech companies.
  • Entrepreneurs: Discover how public biotech firms like Protara Therapeutics, Inc. (TARA) approach market challenges.

What the Template Contains

  • Operating and Balance Sheet Data: Pre-filled Protara Therapeutics historical data and forecasts, including revenue, EBITDA, EBIT, and capital expenditures.
  • WACC Calculation: A dedicated sheet for Weighted Average Cost of Capital (WACC), including parameters like Beta, risk-free rate, and share price.
  • DCF Valuation (Unlevered and Levered): Editable Discounted Cash Flow models showing intrinsic value with detailed calculations.
  • Financial Statements: Pre-loaded financial statements (annual and quarterly) to support analysis.
  • Key Ratios: Includes profitability, leverage, and efficiency ratios for Protara Therapeutics, Inc. (TARA).
  • Dashboard and Charts: Visual summary of valuation outputs and assumptions to analyze results easily.

No products were found matching.